IP Library Granted Patent US 9,981,998
Granted Patent B2
US 9,981,998 · App. 15/077,802 · Granted May 29, 2018

Water-soluble acetaminophen analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,998
App. No.
15/077,802
Granted
May 29, 2018
Kind
B2
Abstract

The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided.

Claims (25)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 , wherein the compound is a disodium salt of formula (II):

3. A formulation comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. The formulation of claim 3 , wherein the pharmaceutically acceptable carrier is saline.

5. The formulation of claim 3 , further comprising a compound selected from the group consisting of an opioid, non-steroidal anti-inflammatory drug (NSAID), benzodiazepine, and barbiturate.

6. The formulation of claim 3 , further comprising a compound selected from the group consisting of codeine, morphine, hydrocodone, hydromorphone, levorphanol, aspirin, ketorolac, ibuprofen, naproxen, caffeine, tramadol, dextropropoxyphene, methylhexital, diazepam, lorazepam, midazolam, propoxyphene, ketoprofen, flurbiprofen, etodolac, diclofenac, misoprostol, meloxicam, piroxicam, doxylamine, pamabrom, carisoprodol, and butalbital.

7. A substantially pure form of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of treating pain, fever, ischemic injury, or neural injury comprising administering to an individual an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the method comprises administering a formulation comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. The method according to claim 8 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered parenterally.

11. The method according to claim 10 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered intravenously.

12. The method according to claim 10 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered intramuscularly.

13. The method according to claim 10 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered subcutaneously.

14. The method according to claim 8 , wherein the dosage of the compound, or a pharmaceutically acceptable salt thereof, is about 300 mg to about 2.6 g.

15. The method according to claim 14 , wherein the dosage of the compound, or a pharmaceutically acceptable salt thereof, is about 1.3 g to about 1.9 g.

16. The method according to claim 14 , wherein the volume of the dosage is about 1 mL to about 25 mL.

17. The method according to claim 16 , wherein the volume of the dosage is about 10 mL to about 20 mL.

18. The method according to claim 16 , wherein the volume of the dosage is about 1 mL to about 10 mL.

19. The method according to claim 16 , wherein the volume of the dosage is about 5 mL to about 10 mL.

20. The method according to claim 14 , wherein the dosage is administered more than once a day.

21. The method according to claim 14 , wherein the dosage is administered once every other day or less.

22. The formulation of claim 3 , wherein the formulation is a low volume/high concentration formulation.

23. The formulation of claim 3 , wherein the formulation comprises a disodium salt of formula (II):

24. The method of claim 8 , wherein the method comprises administering to an individual an effective amount of a disodium salt of formula (II):

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: NEUROGESX, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 044279/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: MUHAMMAD, NAWEED; BLEY, KEITH R.
To: NEUROGESX, INC.
Reel/Frame 043927/0967 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →